Vaxcyte Advances VAX-31 Infant Phase 2 Dose-Finding Study with First Participants Receiving VAX-31 Optimized Dose
(VACC) VAX-31 Optimized Dose, with Majority of Serotypes Dosed at 4.4mcg and Balance at 3.3mcg, is Designed to Elicit Even Stronger Immune Responses in Infant Population to Protect Against Invasive Pneumococcal Disease (IPD)
Related Questions
How will the Phase 2 dose-finding results affect VACC's short‑term stock valuation and trading volume?
What is the projected timeline for data readout and potential regulatory milestones, and how does this align with the company's cash runway?
How does VAX‑31's optimized dosing strategy and expected efficacy compare with existing pneumococcal vaccines and pipeline competitors?